Invex Therapeutics aims to re-purpose a diabetic drug for brain disorders such as idiopathic intracranial hypertension, traumatic brain injury and acute stroke. As the product is already in production and use there is an easy route to entry. Sector: Healthcare Industry: Pharmaceuticals
Supply is being soaked and the price has been slowly appreciating due to accumulation.
BioTech sector with Top 20 holding 80% Market Cap 44m Cash Rich (Circa 10m) IPO at 0.40 Quality Management Price reversal upwardly trending price